Our preclinical data show that PNT2258 demonstrates good single-agent activity and show additive effect with rituximab in DLBCL where the t(14;18) rearrangement exists (WSU-DLCL2) and synergistic activity against Daudi-Burkitt’s, suggesting that targeting BCL-2 can potentiate other therapies. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.